Clearside Biomedical, Inc.

Clearside Biomedical is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye. Their proprietary Suprachoroidal Space (SCS®) injection platform, utilizing the patented SCS Microinjector®, allows for a non-surgical, in-office procedure to deliver a variety of treatments directly to the site of disease in the macula, retina, or choroid. This innovative approach aims to preserve and improve vision for patients with sight-threatening eye conditions.

Clearside has already achieved a significant milestone with the FDA approval of their first product, XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use. Currently, they are developing their own pipeline of small molecule product candidates, such as CLS-AX (axitinib injectable suspension) for wet AMD, which is in Phase 2b clinical testing. Additionally, Clearside actively collaborates with other companies to leverage their SCS injection platform for various ophthalmic therapeutic innovations.

Clearside Biomedical is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). They are dedicated to developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases. Their innovative approach, utilizing their patented SCS Microinjector®, allows for targeted and compartmentalized delivery of therapies directly to the site of disease in a non-surgical, in-office procedure. Clearside is developing its own pipeline of small molecule product candidates and strategically partners its SCS injection platform with other companies to advance the treatment of sight-threatening eye conditions.

Clearside Biomedical fosters a culture focused on innovation and collaboration. The company prioritizes developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases. They are driven by a strong commitment to pioneering the way in ophthalmic therapies through their unique suprachoroidal space (SCS®) injection platform. Clearside's dedication to partnerships and research underlines a collaborative spirit, further emphasized by their diverse portfolio targeting multiple retinal disorders.